Stock MAGLE MAGLE CHEMOSWED HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Magle Chemoswed Holding AB

Equities

MAGLE

SE0014401014

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 11:24:00 2024-05-10 am EDT 		5-day change 1st Jan Change
32 SEK 0.00% Intraday chart for Magle Chemoswed Holding AB 0.00% +26.98%
Apr. 18 Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 22 Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million. CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 289.4 272.2 345.6 - -
Enterprise Value (EV) 1 289.4 317.6 399 387.6 371.6
P/E ratio 30.8 x 22.3 x 16.8 x 11 x 9.41 x
Yield - - - - -
Capitalization / Revenue - 1.6 x 1.87 x 1.6 x 1.47 x
EV / Revenue - 1.86 x 2.16 x 1.8 x 1.58 x
EV / EBITDA - 10.2 x 9.19 x 6.92 x 5.73 x
EV / FCF - -108,204,770 x - - -
FCF Yield - -0% - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 10,800 10,800 10,800 - -
Reference price 2 26.80 25.20 32.00 32.00 32.00
Announcement Date 2/16/23 2/16/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 170.4 184.8 215.5 234.8
EBITDA 1 - 31.11 43.4 56 64.9
EBIT 1 - 18.01 28.8 38.8 46.1
Operating Margin - 10.57% 15.58% 18% 19.63%
Earnings before Tax (EBT) - 15.08 - - -
Net income 1 9.409 12.17 21 30.8 36.6
Net margin - 7.14% 11.36% 14.29% 15.59%
EPS 2 0.8700 1.130 1.900 2.900 3.400
Free Cash Flow - -2.935 - - -
FCF margin - -1.72% - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 2/16/23 2/16/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q4 2024 Q2 2024 Q3 2024 Q4
Net sales 1 38.65 38.07 57.37 43.6 49.5 53.5
EBITDA 1 - 9.5 9.291 13.6 11.8 11
EBIT 1 - 6.266 5.897 10.1 7.8 6.7
Operating Margin - 16.46% 10.28% 23.17% 15.76% 12.52%
Earnings before Tax (EBT) - - - - - -
Net income 2.884 - - - - -
Net margin 7.46% - - - - -
EPS 2 - 0.4300 - 0.7000 0.5000 0.4000
Dividend per Share - - - - - -
Announcement Date 4/19/23 7/18/23 2/16/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - 45.4 53.4 42 26
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) - 1.46 x 1.23 x 0.75 x 0.4006 x
Free Cash Flow - -2.94 - - -
ROE (net income / shareholders' equity) - 9.5% - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - 15.1 - - -
Capex / Sales - 8.87% - - -
Announcement Date 2/16/23 2/16/24 - - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Magle Chemoswed Holding AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MAGLE CHEMOSWED HOLDING AB Stock Magle Chemoswed Holding AB
+26.98% 31.89M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MAGLE Stock
  4. Financials Magle Chemoswed Holding AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW